A	B	C
1	Main
2		Brand Name	Isentress, fka MK-0518
3		Generic Name
4		Mechanism	Integrase Inhibitor
5		Indication	HIV
6		Price	$9855 per annual cost.
7		Approval	US: October 2007, Europe: December 2007.
8		Clinical Trials
9			p2 data showed 64-84% of patients on 518 and background therapy achieved HIV RNA <400copies/mL
10
11			Phase II dose-ranging study
12			MK-0518 + Viread or? Epivir shows 85-95% of patients had viral reduction <50copies/ml vs Sustiva 92% with same agents
13			data presented at Toronto 2006 - showed faster reduction than Sustiva
14
15
16
17			p3 BENCHMRK-1 -2